While OS is still the king of the oncology endpoints, experts note it may soon be phased out due to the introduction of ...

Endpoint protection, often abbreviated as EPP, is a system designed to secure each endpoint of an enterprise network from potential cyber threats. It's a security approach that focuses on each device ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Attackers are turning to generative AI to hunt for the easiest endpoints ...

Enanta Pharmaceuticals remains a Buy as zelicapavir shows promise in RSV trials; strong financials support growth. Read why ...

Enata Pharmaceuticals said it didn't meet its primary endpoint in a Phase 2b study of zelicapavir, its proposed treatment for Respiratory Syncytial Virus, or RSV, in high-risk adults.

Kura Oncology (KURA) and Kyowa Kirin announced the Journal of Clinical Oncology published the full results from the pivotal ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more Bad actors continue to capitalize on the ...

MSK played a central role in the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC)’s landmark decision in April 2024 to accept measurable residual disease (MRD) as an ...

Researchers hope that changes to total hip BMD will get approval from the FDA as a surrogate endpoint for clinical trials of ...

Kala Bio missed the primary endpoint in the study for its treatment of Persistent Corneal Epithelial Defect, an eye defect, and said it would stop development of the drug, called KPI-012. The company ...

Kala Bio announced that CHASE (NCT05727878), its phase 2b clinical trial of KPI-012 for persistent corneal epithelial defect ...